Stocks › REGN
REGENERON PHARMACEUTICALS, INC.
REGN·Nasdaq·
United States·USD
United States·USD$738.72
+12.25 (+1.69%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
REGN
REGENERON PHARMACEUTICALS, INC. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
REGNS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of REGN by members of U.S. Congress · 237 on record · 8 in the last 12 months
Whale Activity
Position changes in REGN reported for 2026-09-30 by 1 tracked institutional filer
- Increased0
- New0
- Held0
- Decreased0
- Closed0
- No prior filing1
| Filer | Shares | Value | Change |
|---|---|---|---|
| JIA INVESTMENT ALLIANCE PTE. LTD. | 67.3K | $51.0M | — |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by REGN insiders, by quarter · Form 4
Recent Insider Transactions
6,927 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| McCourt MarionEVP Commercial | Sale | −1,131 | $857.39 | $970K | Sep 3, 2026 | Form 4 ↗ |
| Guarini KathrynDirector · Director | Sale | −400 | $850.00 | $340K | Sep 2, 2026 | Form 4 ↗ |
| McCourt MarionEVP Commercial | Sale | −1,215 | $850.00 | $1.0M | Sep 2, 2026 | Form 4 ↗ |
| Guarini KathrynDirector · Director | Sale | −400 | $800.00 | $320K | Aug 10, 2026 | Form 4 ↗ |
| Zoghbi Huda YDirector · Director | Sale | −800 | $800.00 | $640K | Aug 10, 2026 | Form 4 ↗ |
| RYAN ARTHUR FDirector · Director | Sale | −200 | $650.15 | $130K | Jul 2, 2026 | Form 4 ↗ |
| RYAN ARTHUR FDirector | Sale | −2 | $714.13 | $1K | May 1, 2026 | Form 4 ↗ |
| RYAN ARTHUR FDirector | Sale | −1 | $712.09 | $712 | May 1, 2026 | Form 4 ↗ |
| RYAN ARTHUR FDirector | Sale | −5 | $711.49 | $4K | May 1, 2026 | Form 4 ↗ |
| RYAN ARTHUR FDirector | Sale | −2 | $710.87 | $1K | May 1, 2026 | Form 4 ↗ |
| RYAN ARTHUR FDirector | Sale | −6 | $709.45 | $4K | May 1, 2026 | Form 4 ↗ |
| RYAN ARTHUR FDirector | Sale | −4 | $707.40 | $3K | May 1, 2026 | Form 4 ↗ |
| RYAN ARTHUR FDirector | Sale | −7 | $706.74 | $5K | May 1, 2026 | Form 4 ↗ |
| RYAN ARTHUR FDirector | Sale | −14 | $705.56 | $10K | May 1, 2026 | Form 4 ↗ |
| RYAN ARTHUR FDirector | Sale | −15 | $704.28 | $11K | May 1, 2026 | Form 4 ↗ |
| RYAN ARTHUR FDirector | Sale | −24 | $703.46 | $17K | May 1, 2026 | Form 4 ↗ |
| RYAN ARTHUR FDirector | Sale | −15 | $702.46 | $11K | May 1, 2026 | Form 4 ↗ |
| RYAN ARTHUR FDirector | Sale | −5 | $701.76 | $4K | May 1, 2026 | Form 4 ↗ |
| RYAN ARTHUR FDirector | Sale | −40 | $779.71 | $31K | Apr 1, 2026 | Form 4 ↗ |
| RYAN ARTHUR FDirector | Sale | −4 | $778.24 | $3K | Apr 1, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding REGN · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 3.3M | $2.04B | 0.09% | Jun 30, 2026 |
| Dodge & Cox Stock Fund Dodge & Cox Funds | 3.1M | $1.95B | 1.64% | Jun 30, 2026 |
| VANGUARD 500 INDEX FUND VANGUARD INDEX FUNDS | 2.6M | $1.61B | 0.10% | Jun 30, 2026 |
| Invesco QQQ Trust, Series 1 | 2.2M | $1.36B | 0.28% | Jun 30, 2026 |
| Putnam Large Cap Value Fund | 1.2M | $878.6M | 1.59% | Jul 31, 2026 |
| iShares Core S&P 500 ETF iShares Trust | 1.4M | $857.0M | 0.10% | Jun 30, 2026 |
| VANGUARD HEALTH CARE FUND VANGUARD SPECIALIZED FUNDS | 1.1M | $817.7M | 2.14% | Jul 31, 2026 |
| Fidelity 500 Index Fund Fidelity Concord Street Trust | 1.3M | $793.1M | 0.10% | May 31, 2026 |
| State Street(R) SPDR(R) S&P 500(R) ETF Trust | 1.2M | $755.1M | 0.10% | Jun 30, 2026 |
| VANGUARD MID-CAP INDEX FUND VANGUARD INDEX FUNDS | 1.1M | $696.0M | 0.31% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list REGN's shares (CUSIP 75886F107), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming regeneron pharmaceuticals as client
- CRANE STRATEGIESREGENERON PHARMACEUTICALS, INC. · 2026 Q2 · BUD$50K
Filing ↗ - REGENERON PHARMACEUTICALS, INCREGENERON PHARMACEUTICALS, INC · 2026 Q2 · HCR, MMM, CPT, TRD$630K
Filing ↗ - ARNOLD & PORTER KAYE SCHOLER LLPREGENERON PHARMACEUTICALS, INC. · 2026 Q2 · HCR$50K
Filing ↗ - BGR GOVERNMENT AFFAIRSREGENERON PHARMACEUTICALS, INC. · 2026 Q2 · HCR$90K
Filing ↗ - CHECKMATE GOVERNMENT RELATIONSREGENERON PHARMACEUTICALS INC. · 2026 Q2 · HCR$90K
Filing ↗
Government Contracts
Federal awards to regeneron pharmaceuticals · USAspending
$1.25BAwarded · 2 contracts on record
U.S. Patents
Recent USPTO applications naming REGENERON PHARMACEUTICALS, INC.
No USPTO patent applications found for REGENERON PHARMACEUTICALS, INC..
Annual Financials
From REGN's 10-K filings · XBRL
No annual XBRL figures on record for REGN. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
No stock splits in REGN's price history.
About REGENERON PHARMACEUTICALS, INC.
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersTARRYTOWN, NY
IncorporatedNY
SEC CIK0000872589 ↗
Former namesREGENERON PHARMACEUTICALS INC